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Introduction
Substance abuse and addiction incurs huge costs to society every 
year - more than £15 billion in the UK alone. The bulk of this expense 
comes from drug-related crime and death, but close to £500 million is 
spent annually by the NHS to treat all manner of physical and mental 
conditions directly related to substance misuse.1 Drug addiction is 
considered a ‘disease of the brain’ because prolonged substance abuse 
(SA) can result in permanent changes to its physical structure and 
neurochemistry2 – and until recently, it was largely treated as a problem 
specifically reserved for men. Research surrounding substance misuse 
and treatment has historically focused on men and male drug-abuse - 
due in large part to the outdated view that, women are far less affected 
by the disease.3 More recently, science and society are beginning 
to acknowledge that females also frequently fall victim to drug use 
and addiction; but researchers recognise that there is variation in the 
substances which are more commonly abused between the sexes4,5 
and the underlying causality. Increasingly, research is beginning to 
recognise sex-differences in all phases of abuse and across a variety 
of different substances – highlighting the importance of specifically 
tailored treatment types. Studies show that men and women tend 
to fall into abuse for different reasons, which offers an explanation 
as to why they often respond so differently to treatment. Marked 
differences have been noted across human and animal models6 
and these variances extend beyond initiation and effectiveness of 
treatment. Gender-specific differences are also observed in patterns of 
criminal behaviour, involvement with dealing and levels of traditional 
employment, to name but a few.7
This paper will outline the impact of societal pressures, 
psychological burdens and biological influences on women and 
substance abuse, (Figure 1). It will also consider the implications 
of these underlying sex differences on substance abuse treatment 
and makes suggestions regarding the approaches taken to treating 
addicted women. Many different types of treatment are available, 
but individuals can fall into a cycle of substance abuse for numerous 
different reasons. The causation, and trigger-factors that lead to SA 
can heavily impact the effectiveness of certain treatment types.8 All 
three factors are not mutually exclusive and frequently cross-over and 
intertwine. Biological differences between the sexes include elements 
such as pharmacokinetics, hormonal variations and metabolism but 
also neurochemical and structural differences which closely relate 
to the psychological variances. Societal and cultural pressures also 
affect women psychologically, as the series of unattainable ideals 
placed upon them begin to manifest in self-objectification and 
subsequent mental disorders. The prevalence of these co-occurring 
disorders is often a triggering factor for abuse, therefore these also 
need to be addressed and treated simultaneously for SA treatment to 
be successful. 
Figure 1 A simplified breakdown of the main risk factors associated with 
drug addiction. Adapted from National Institute on Drug Abuse.2
Discussion
Societal stresses and support systems 
It has been documented that reports of pre-treatment sexual abuse 
and trauma earlier in life are considerably higher in women than 
men,9,10 and links have been made between the sexual objectification 
(SO) of women and drug misuse in all guises.11 Sexual objectification 
is a broad-term, used to describe a variety of behavior’s - ranging 
from the relatively ‘mild’ and extending to cover sexual harassment 
and assault.12 In 1997, Fredrickson and Roberts developed the 
“Objectification Theory” which postulates reasonable linkages 
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between SO and disproportionately high instances of mental-health 
disorders including disordered eating and sexual dysfunction. This 
study summarises how SO affects women at each life-stage, and speaks 
about elevated feelings of shame and increased risk of depression and 
anxiety.12 The theory has since been revisited and extended to suggest 
that instances of objectification may increase the risk of drug use and 
misuse in women (Figure 2).11
Figure 2 The relationship between, and pathway from, sexual objectification 
to substance abuse. Adapted from Carr et al.11
Patriarchal culture: Generally, modern-society is still distinctly 
patriarchal; which offers some explanation as to why SO is still such a 
prevalent issue for women. However, sexual objectification is just one 
of many factors and societal pressures which may be contributing to 
the observable rise in addiction among women. First-world attitudes 
towards women are slowly changing – allowing them the opportunity 
to be increasingly ambitious and successful in their careers. But even 
career-driven women often remain the main care-providers within 
their families, expected to always place the needs of their loved ones 
ahead of their own - mounting enormous pressure and increasing 
stress and anxiety.13 This trend has been observed and research has 
confirmed that women are at substantially higher risk of suffering 
with depression and anxiety disorders14 and are more likely to abuse 
prescription drugs, specifically.15
Sexual objectification within the media: Figure 2 is demonstrative 
of the pathways from SO to substance abuse, but also refers to self-
objectification – another factor which affects women’s mental health 
and can ultimately lead to SA. Syzmanski’s 2011 study extends 
beyond ‘direct’ sexual objectification/victimisation; and suggests that 
cultural messages and those perpetuated by the media also impact the 
likelihood of women resorting to drugs. Specifically, the effects of 
living within cultures where objectification of the female body is the 
norm, and singular-ideals of what it means to be a woman and to be 
considered attractive are constantly reinforced in the media.16 These 
pressures lead to self-objectification and demoralising attempts to 
fulfil these cultural ideals. There is even a suggestion of a relationship 
between SA and the perception of ‘sexiness’, and constant body 
surveillance and self-deprivation. 
Home life and support: Other research has indicated that drug abuse 
which is initiated during adolescence, is likely to be worsened by a 
weak family support system, or at least a perceived lack of support.17 
The same study also established a strong positive correlation between 
familial conflict or stresses and increased levels of substance abuse. 
Both findings signify the importance of strong family relationships 
and external support-systems, and show that the absence of either 
can have negative implications for substance abusers. Interestingly, 
not all societal factors seem to influence men and women’s drug 
use differently - studies have concluded that there is generally no 
difference in the sociodemographic of male and female drug abusers.18 
However, it is reported that the initiation of drug-use in women can 
often be influenced by and attributed to a partner who already abuses 
a given substance.19 Similarly, drug-using women are far more likely 
than men to be romantically or sexually involved with a partner who 
also abuses illicit drugs and less likely to be with a man who does not 
use drugs at all.20 These conclusions indicate that home-life stresses 
and support-systems continue to impact drug abuse into adulthood.
Domestic violence and substance abuse: One particularly severe 
and troublesome example of this, is the correlation between domestic 
violence and substance abuse. Reports of domestic violence against 
women are worryingly high, and research suggests that survivors of 
domestic abuse may be up to 5 times more likely to fall into patterns 
of alcohol and drug abuse than women that have not suffered the 
same experiences.21 A number of hypotheses have been developed in 
an attempt to rationalise or explain these statistics; some literature 
suggests that women may self-medicate22 as a means to deal with 
the trauma caused by the violent episodes which correlates with 
explanations relating to various other forms of trauma and suffering. 
A study by Macy et al.21 discusses the co-occurrence of violence 
inflicted by a partner, substance abuse in women and the effect each 
variable may have on the other. A suggestion is made that some 
women feel unable to remove themselves from the violent setting, as 
the individual inflicting the violence may be the same individual who 
facilitates their access to any given substance.21 This research relates 
back to the work of Miller20, who proved that women who abuse drugs 
are very likely to also have a substance-abusing partner.20 The same 
study also included accounts of verbal, psychological, emotional 
and sexual partner-violence as well physically violent experiences. 
It also addresses complicating factors including; incidences of 
violence in earlier life and childhood, substance initiation as a direct 
result of a violent partner, drug use that preceded partner-violence, 
and a reluctance to seek protection and treatment through fear of the 
repercussions – particularly in relation to children and child custody.21
Psychological Impact
 As previously discussed, research-material focusing on female 
substance abusers and addicts is distinctly lacking, and findings 
from studies using male-only samples are frequently applied to the 
whole population.23 Previous research has suggested sex-differences 
in many of the biological and psychological responses associated 
with drug use and more recently, research has begun to emphasise 
the importance and impact of psychological differences and gender-
specific experiences16 on SA. Many of the experiences and variables 
that have been addressed in the previous section, must also be 
considered in terms of the mental damage they inflict. For example, 
societal pressures such as sexual objectification can culminate in a 
number of psychological implications. In these instances, it is the 
abnormal thinking associated with the mental disorders which will 
ultimately trigger the onset of substance abuse. However, sexual 
objectification and abuse in adolescence or adulthood is only one 
predictor of psychological harm which may cause women to turn to 
illicit substances. 
Adverse childhood experiences: Trauma in the earlier stages of life 
is more frequently reported by female substance-abusers than male.10 
Studies as far back as the 1980’s have postulated a link between 
sexual-abuse in childhood, and the un-resolved issues relating to it, 
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with a propensity for addictive behaviours in later life.24 Fernández-
Montalvo et al.,25 proposed three possible explanations for the strong 
association between physical, sexual and psychological mistreatment 
and the development of SA. Firstly, that the impact of the abuse is 
severe enough to result in the development of post-traumatic stress 
disorder (PTSD) and that in these instances substance abuse is used 
to relieve the symptoms of the condition. The second explanation 
proposes that individuals who abuse drugs are more vulnerable to 
distress and traumatic ordeals; and that PTSD can be brought about 
as a result of the drug-related trauma. And the final proposition 
suggests that addiction and abuse often co-exist within abnormal 
family situations.25 Without question, there are long-lasting effects 
of childhood trauma of any sort – and research has shown that 
instances of childhood sexual abuse (CSA) are elevated in individuals 
with alcohol and drug abuse issues.26,27 Research has also suggested 
that CSA is frequently co-occurring alongside other traumatic and 
damaging measures,28 increasingly the likelihood of psychological 
damage. In 2000, a study by Kendler et al.,29 was able to prove that 
exposure to sexual abuse in childhood lead to increased instances of 
both psychological conditions and substance abuse in adult women. 
This suggests that drugs or alcohol may serve a functional role for 
survivors of childhood sexual abuse, as a means to cope with the 
psychological trauma caused by these early life experiences.29 
Lifetime abuse seems to have detrimental consequences across a 
number of variables, with negative effects beyond the increased 
propensity for substance abuse. A comparison of treatment seeking 
abused and non-abused drug addicts, found that the implications of 
abuse penetrated all areas of the individual’s life. Addicts who had 
suffered abuse had a greater number of familial problems, were less 
likely to be able maintain permanent employment, had more problems 
with friends and peers and suffered more frequently and severely with 
psychological disorders25 (Table 1).
Table 1 A comparison of maladjustment variables between abused and non-abused individuals seeking treatment for SA25
Lifetime abuse
 All Yes(n=115) No(n=135)  
 n n(%) n(%) n(%)  χ2
Family maladjustment
Problems with
Mother 247 75(30.4%) 42(37.2%) 33(24.6%) 4.6*
Father 239 76(36.0%) 50(45.9%) 36(27.8%) 8.5**
Sibiling 239 78(32.6%) 46(41.1%) 32(25.2%) 6.8**
Partner 237 46(61.6%) 85(76.6%) 61(48.4%) 19.8***
Son/Daughter 120 15(12.5%) 10(18.2%) 5(7.7%) 3
Social maladjustment
Problems with
Intimate friends 242 63(26.0%) 42(38.2%) 21(15.9%) 15.5***
Neighbors 247 31(12.6%) 18(15.8%) 13(9.8%) 2
Work Colleagues 247 71(28.7%) 40(35.4%) 31(23.1%) 4.5*
Labor maladjustment
Without permanent job during the last 3 years 252 38(15.1%) 22(19.1%) 16(11.9%) 2.6
Psychological maladjustment
Depressive Problems 250 130(52.0%) 77(67.0%) 53(39.3%) 19.1***
Anixety Problems 250 152(60.8%) 83(72.2%) 69(51.1%) 11.6**
Violence problems 250 99(39.6%) 60(52.2%) 39(28.9%) 14.1***
Suicide ideation 250 99(39.6%) 56(48.8.2%) 43(31.8%) 7.4**
Suicide attempt 247 40(16.2%) 24(21.3%) 16(11.9%) 3.9*
*p<0.05, **p<0.01, ***p<0.001
Comorbidity of substance abuse disorders and mental disorders: 
The relationship between psychiatric disorders and SA disorders has 
been addressed, to a certain extent, in relation to PTSD, depression 
and anxiety. Comorbidity of the two conditions is well-established 
throughout literature, and suggests linkages between a number of 
disorders; ranging from depression and mood-disorders to anti-social 
personality disorder and ADHD.30,31 Substance abuse among sufferers 
of mental illness is undeniably prevalent, but the explicit nature of 
the relationship is debated by different researchers. Many studies 
suggest that specific psychiatric disorders are a key trigger-factor for 
the subsequent misuse of substances,32 while others demonstrate that 
these mental disorders are in-fact a direct result of substance abuse.33 
Merikangas30 suggested that previous research had been unsuccessful 
in establishing a single mechanism to explain the comorbidity of these 
disorders due to the extensive number of comorbid diseases that exist. 
Moreover, the way psychiatric disorders are expressed can be affected 
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by the substances that are abused and similarly, SA may manifest 
differently in association with mental disorders.30 Comorbidity 
needs to be carefully considered when treating either disorder, as 
interventions for both are necessary for successful recovery.8 When 
the two types of disorder are examined separately, gender-specific 
variances are frequently observed and reported.34 However, research 
is generally inconclusive when attempting to establish the presence, 
or absence, of sex-differences in relation to comorbidity.
It is estimated that substance abuse increases the chances of 
developing depression by a factor of 4.78 – making substance abusers 
almost 5 times more likely to suffer from depression than non-abusers. 
Many of the environmental and social factors discussed earlier which 
are shown to increase the probability of substance abuse, such as a 
disruptive home life and elevated stress levels, are also associated with 
depression. Research has also shown that women are more likely to 
suffer from depression than men,14 and may therefore turn to a number 
of different substances in an attempt to self-medicate. This hypothesis 
has been investigated and the findings demonstrate that several 
illicit drugs stimulate responses from the neurotransmitters, which 
are affected by depression and mood disorders. In some cases, these 
pharmacological responses can temporarily combat Serotonin and 
Dopamine deficiencies, which are observed in individuals suffering 
from depression.35 This study perfectly encapsulates the crossover 
between psychological and biological factors by demonstrating how 
variances in one element can affect the other.
Biological impact 
Substance-related gender differences have been observed in the 
findings of numerous studies – the suggestion being that woman 
are more susceptible to drug addiction than men, with a greater 
vulnerability particularly in the earlier stages of use that precede 
and lead to addiction.3 There is evidence to support a number of sex-
differences, which are observed beyond psychological and cultural 
variances, which are based in physiology and add an additional 
dimension to gender-related research in this field. Studies have 
shown pharmacokinetic differences in the way drugs are processed 
by the two sexes. In 2014, Rambousek et al.36 applied this theory to 
an animal model and could demonstrate that, following exposure to 
amphetamine and methamphetamine, females displayed considerably 
higher levels of both substances in the brain and blood plasma. The 
results of this study suggested that females are at a greater-risk of 
toxicity and dependence.36 A number of biological causes for these 
differences has been suggested; with evidence generally supporting 
the impact of ovarian hormones and menstrual-cycle fluctuations on 
behavioural and neurochemical responses to illicit drugs.5,37,38 
Hormonal influences: The three phases of the human menstrual 
cycle which are the focus of most substance-abuse research are; 
follicular, periovulatory and luteal. A study by Lynch in 2002, 
established a positive correlation between increased oestrogen levels 
and enhancement of the “positive” effects and behavioural responses 
associated with psychostimulants, such as methamphetamine.5 There 
is also evidence to suggest that the relative levels of oestrogen 
and progesterone throughout the menstrual cycle can affect the 
pharmacokinetic response of the body to a number of different 
drugs. The same heightening effect can be seen when progesterone-
levels are comparatively low and the effects of oestrogen are rather 
uninhibited.5 These hormonal influences affect all amphetamine-type 
drugs which may indicate why they are among the substances most 
commonly abused by pregnant women.39 Other studies have reported 
similar findings in relation to cocaine and a greater ‘high’ during the 
follicular phase of the menstrual cycle.5 In contrast, progesterone 
seems to have the opposite effect and has even be associated with a 
reduction of cravings in female cocaine users.40 However, Quinones-
Jenab and Jenab suggest that the diminishing effect of progesterone 
on the pleasant stimulation is potentially dangerous. They speculate 
that women may be at a higher risk of overdose if they attempt to 
reach their usual high during the luteal phase of menstruation when 
progesterone levels are at their lowest.41 Menstrual-cycle fluctuations 
have also been shown to affect the pharmacokinetic properties of a 
number of different drugs; from rates of absorption to gastrointestinal 
motility of orally administered drugs and bioavailability.5,42 These 
changes are not purely due to hormonal variation; physiological 
changes that occur throughout the menstrual cycle can also affect 
some of pharmacokinetic effects of drugs. Basal metabolic rate, 
heart rate, blood pressure, water retention and immune function all 
undergo variation through the menstrual cycle, in-line with hormonal 
fluctuation.42 
Stigmatisation 
A number of studies have acknowledged elevated levels of stigma 
and social disapproval towards female drug users when compared to 
men,5,43 which offers an explanation for the lack of research focusing 
on female drug use and addiction. Two reasons for this imbalance have 
been postulated; one rooted in the societal views and expectations of 
‘female virtue’ and the other based upon traditional gender roles and 
the perception of women as nurturers and care-givers.43 However, 
a study by Nicolaides in 1996 suggested that as societal attitudes 
towards women are slowly changing, so too are opinions surrounding 
their drug use – the findings suggest that stigmatisation towards 
women is beginning to decrease and that female SA is becoming 
more ‘acceptable’ in the eyes of society.44 Other research suggests 
that the sex-differences in frequency of drug use can be attributed to 
differences in opportunity rather than fear of judgement or criticism.5
Drug acquisition
Drug acquisition, and participation in any level of the drug market, 
is determined by opportunity. A 1993 survey on drug abuse revealed 
that men have far greater access to marijuana, cocaine, hallucinogens 
and heroin than women do.45 Research has shown that there are 
distinct gender-differences in the opportunities that are presented and 
the strategies used by men and women to obtain drugs – the general 
consequence of which is that women have limited involvement in the 
profitable activities, such as distribution, and often utilise different 
routes of acquisition.46 Griffin and Rodriguez describe ‘sexist and 
segregated’ systems of drug-distribution where women occupy purely 
subsidiary roles and are governed by men. The same study also 
suggests that familial ties, such as being married or having children, 
will likely affect men and women’s ability to expand their social 
networks differently.46 This is relevant because a strong association 
has been established between social networks and access to all types 
of illegal opportunities, including drug market participation – which 
may explain why women are less likely to acquire drugs in face-
to-face cash transactions than men.46 This may be one of a number 
of factors fuelling the increasing popularity of alternative routes of 
acquisition; in particular, the growing use of the internet to facilitate 
drug procurement.
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Drug accessibility: Online pharmacies: Although the majority of 
research around the area is relatively recent, drug use itself is not 
a modern concept. Drugs have been used and abused historically 
across many different cultures and countries – with the first known 
record of Opium made more than 5400 years ago.47 However, it is 
not necessary to delve so far into the past to be able to observe the 
changes that the modern world has had on the attainment and use 
of illicit substances. Since the 1990’s, the internet has become an 
increasingly integral part of our daily lives and it is now possible to 
purchase products and services of all types quickly and conveniently. 
With this, has come the ability to acquire a large number of medicines 
and medical supplies – including those, which are usually reserved 
for patients with a medical prescription from a registered healthcare 
professional.48 It is now easier than ever to obtain a huge number of 
different pharmaceutical products, a service that has the potential to 
be enormously advantageous by increasing convenience and lowering 
costs.49 Unfortunately, the access to controlled drugs via the internet 
provides endless opportunities for its misuse – including the illicit 
sale and acquisition of pharmaceuticals.50,51 The scale of which has 
been demonstrated by a study carried out by the National Centre 
of Substance Abuse (CASA), which suggests that ~85% of internet 
pharmacies are distributing controlled medication without requiring 
the customer to provide proof of prescription.52 Table 253 shows the 
availability of 11 different controlled drugs at 175 online pharmacies, 
and how many required proof of prescription before purchase. These 
“pharmacies” assist substance abusers, from every socioeconomic 
group and of all ages54 to access substances which feed their 
dependency. In the past 15 years there has been a substantial increase 
in the abuse of prescription drugs55 – a timeline which corresponds 
with the growth and prevalence of internet pharmacies.56 
Table 2 The availability of 11 controlled substances at online pharmacies, with and without a prescription53
 All Ops, N= 175 Prescription Ops, N=39 No-Prescription Ops N=136
 n % n % n %
Sidenafil 161 92 37 94.9 124 91.2
Fluoxetine 144 82.3 38 97.4 106 77.9*
Tramadol 128 73.1 31 79.5 97 71.3
Amitriptyline 116 66.3 33 84.6 83 61.0*
Valproiv acid 58 33.1 25 64.1 33 24.3*
Alprazolam 39 22.3 13 33.3 26 19.1
Codeine/hydrocodone 36 20.6 12 30.8 24 17.7
Phentermine 26 14.9 9 23.1 17 12.5
Methylphenidate 10 5.7 6 15.4 17 12.5
Stanozolol 7 4 4 10.3 3 2.2*
Amphetamine 4 2.3 4 10.3 0 0†
*Fisher’s test: p<0.05. 
†Fisher’s test: not performable
Counterfeit pharmaceuticals: Hidden beneath the cover of the 
legitimate online trade of regulated substances, is a large and 
rapidly expanding ‘black-market’, which facilitates the trade of 
unapproved and counterfeit pharmaceutical products.51 Leading drug 
manufacturers have proposed that around 2 million. UK residents 
purchase prescription medication online every year.57 Estimates 
suggest that imitation drugs make up over 50% of this online market,53 
meaning that less-than-half of these consumers are receiving genuine 
pharmaceutical products and could be ingesting any potentially fatal 
chemical-cocktail. The impact of which will affect individuals seeking 
to use the drugs for recreational or non-medical purposes as well as 
those treating genuine medical conditions.58 Even discounting the 
counterfeit products, it’s abundantly clear how these internet sales can 
enable an individual to exploit and misuse prescription drugs which 
they would otherwise have limited, or no, access to.
Online pharmacies and women: The three types of prescription drug 
most commonly misused are; opioids, sedatives and stimulants.59 For 
a number of reasons, online access to these classes of drug are likely 
to have a greater impact on women than men. Generally, women are 
at a considerably higher risk of suffering with insomnia, depression 
and anxiety disorders14 and are therefore more likely to turn to drugs 
in order to cope with anxiety and periods of stress.60 Consequently, 
it would be reasonable to assume that the number of women in 
possession of legitimate prescriptions to treat these disorders is 
greater than the number of men. However, the possession of a valid 
prescription does not guarantee that the recipient is using the drugs for 
their intended purpose. A 2014 study by Worley and Thomas exposes 
the phenomenon known as “doctor-shopping” – where women obtain 
medication from several different prescribers for non-medical use.61 
Other studies have shown that women are more likely to abuse drugs 
obtained with a legitimate prescription than men - proving that this 
behaviour is not uncommon, and rather characteristic, of women 
who abuse prescription medication.62 Research has confirmed that 
doctor-shopping is one of the most common routes for diverting 
prescription drugs away from the legal market,63 proving that even 
‘legitimate exposure’ to these substances can lead to both deliberate 
and unintentional misuse.
Gender specific substance abuse treatment 
Mechanisms to access and acquire drugs are not the only element 
of substance abuse to have changed and adapted with modern life. 
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We are now also beginning to see a shift in the manner with which 
substance abuse treatment is administered to sufferers – including a 
greater sensitivity towards the unique needs of women.
Unique health concerns: The differences between male and female 
substance abusers are far-reaching and fundamental to the development 
of effective treatment plans. Physiology and hormonal variation must 
be considered, but the lasting effects of gender-specific experiences, 
co-occurrence of physical or psychological disorders and cultural 
pressures are equally as important. This was concisely summarised 
in 2009 by the US Department of Health and Human Services, who 
released a document stating that; “differences between women and 
men in genetics, physiology, anatomy, and sociocultural expectations 
and experiences lay the foundation that women have unique health 
concerns related to substance use disorders as well as elevated risk 
for certain co-occurring physical and mental issues or disorders”.39 A 
large proportion of women entering substance-abuse treatment have 
experienced abuse or trauma of some kind throughout their lives – be 
that physical/domestic, in childhood, psychological or sexual abuse. 
They are also far more likely have a partner that also abuses drugs20 
but frequently have children and other dependent family members 
to consider when initiating treatment.21 For this reason, women’s 
recovery tends to be heavily associated with repairing relationships 
and the development of a healthy support system.64 Substance abusing 
mothers require greater attention still and additional considerations 
must be made, particularly regarding access to childcare.65 Studies 
show that when provision is made to allow a woman’s children to be 
present with her during treatment, retention rates are higher, and the 
integration of a family dynamic is generally beneficial.64
Pregnancy: In the same way that it is important to tailor substance 
abuse treatments specifically to the needs of addict-mothers,64 a family-
centric approach to recovery is equally critical for pregnant women. 
Additional medical risks and complications when substance-abuse 
occurs during pregnancy. Prenatal drug use is incredibly dangerous 
for the unborn child and is associated with miscarriage, premature 
delivery, cognitive problems and neonatal abstinence syndrome 
to name but a few.66 However, studies suggest that participation in 
prenatal treatment for substance abuse can improve the health and 
outcomes for both the mother and offspring.67,68 Unfortunately, the 
negative consequences for the children do not end at birth – postnatal 
substance abuse is heavily associated with instances of child abuse 
and neglect and if abuse persists, authorities will most-likely intervene 
and the child may be removed from their care.65 The first barriers to 
treating pregnant women arise when attempting to identify those in 
need and then successfully encouraging them to seek help. Women 
who use drugs or suffer from addiction generally face substantially 
more criticism than men.5 The disapproval and judgement increases 
exponentially if the woman in question is pregnant - women may 
be reluctant to come forward because they are ashamed, fear losing 
custody or risk of prosecution.65 
Interventions for co-occurring conditions: Many women turn 
to substance abuse to cope with a number of cultural, societal and 
personal pressures.11 The internal stress caused by these mounting 
burdens and pressures, has been associated with the development a 
number of psychological disorders. Comorbidity influences substance 
abuse and treatment in a number of ways, and these vary with the 
associated disorders and the way they interact with one another 
and manifest in the individual.30 Research has shown substantially 
increased incidences of a large number of psychiatric disorders in 
substance abusers; and both conditions will require simultaneous 
intervention for treatment of either one to be entirely successful.8 
Relative to the general population, mood and anxiety disorders are 
more common in women for a number of reasons. In combination with 
the elevated rates of depression and anxiety seen in substance abusers, 
this needs to be carefully assessed and considered before attempting to 
treat female addicts. Across their lifetime, women are far more likely 
to be subjected to abuse and trauma than men.10 These experiences 
can be incredibly damaging to an individual, and if they are not 
properly processed or addressed can develop into various psychiatric 
problems;25 even as severe as post-traumatic stress disorder. The 
co-occurrence of these two conditions is particularly challenging to 
treat.69 It has been suggested that women who have suffered to this 
extent, use substance abuse as a form of self-medication to remedy the 
adverse symptoms that are associated with the condition.25 In cases 
like this, substance use is elicited as a coping mechanism. Therefore, 
it is imperative that the underlying trauma is treated and rectified – 
without making this a priority, it will not be possible to successfully 
treat the associated addiction.
Exploiting biological differences to develop novel treatment types: 
Studies investigating the impact of gonadal and ovarian hormones has 
revealed the attenuating effects of elevated progesterone levels on 
cocaine use and cravings, particularly in women.3,40 This discovery has 
prompted some researchers to consider the possibility of developing 
progesterone-based medications to treat cocaine addiction.3,38,41 Early 
data suggests that applications to men may be limited but that higher 
concentrations would need to be tested to confirm this.40
Recommendations: The main adjustments that should be made to 
female-specific substance abuse treatment, are rooted in causation 
and environment. Because, in women specifically, substance abuse 
is frequently caused or aggravated by past experiences of trauma and 
unbalanced lifestyles which culminate in psychiatric disorders.25,29 All 
of which are complicating factors that impact treatment and need to 
form a part of the original treatment-plan. Comorbidity should always 
be considered in substance-abusers, but it is so prevalent in women 
that it is even more imperative that it is addressed in the earliest stages 
of assessment and treatment. Home life and family situations are more 
influential factors in women’s substance use than men’s. Routes of 
acquisition should be considered, and an attempt should be made to 
establish who or what is the main source of access in the women’s life. 
Female drug use is frequently facilitated by men21 – specifically sexual 
and romantic partners.19,20 If a woman is placed back into a situation 
where she is surrounded by substance abuse, the risk of relapse is 
hugely increased. Women need to be assisted in improving their social 
networks and home lives - and where appropriate, helped to remove 
themselves from abusive and dangerous environments. Mothers 
and pregnant women should be treated without judgment and with 
compassion; the emphasis should be placed upon improving health 
and family life, rather than adopting a threatening or confrontational 
approach. And critically, women’s mental health should always be 
considered as a primary cause for substance abuse initiation and 
these aberrations should be treated simultaneously. Improving mental 
health and addressing repressed trauma are critical to recovery.
Conclusion
Much of the time, women who suffer with substance abuse 
disorders are simultaneously suffering with at least one other 
condition. Regardless of the specific comorbid disorder that exists 
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alongside the addiction, the implications for treatment are very 
similar. In order to fully recover from a substance abuse disorder, 
the underlying causation and trigger-factors need to be established 
and addressed.8 Sometimes, drugs and alcohol are exploited to block 
out other sources of pain or hurt. Histories of trauma and abuse are 
incredibly prevalent in female substance-abusers.64 If women are 
resorting to drugs as a means to cope with anxiety, depression, stress 
or trauma then the substance abuse really only exists as a symptom 
of that condition.22 In this case, treating only the drug-related issue 
would mean removing the coping mechanism but ignoring the 
cause.29 The likelihood of successful recovery would be substantially 
decreased; and even if it was initially effective, the chances are that 
the individual would quickly relapse or that the pain would manifest 
in another equally harmful way. The individual may, or may not, be 
aware of the presence of these secondary conditions. For this reason, 
counselling should be incorporated into all treatment programs. 
enabling the individual and the treatment provider to establish any 
other issues which need to be addressed, which in turn, will increase 
the likelihood of treatment retention and success in recovery.8 
Mothers are often reluctant to seek help for their addiction 
through fear of the repercussions and authority-involvement.21 When 
treating substance abusing mothers, it is especially important that 
the treatment provider is sensitive and flexible where necessary. 
Women largely take on the role as the main care-provider to their 
families, and this is still true of substance-abusing women. Access 
to childcare, or lack thereof, prevents some women from seeking or 
staying in treatment65 - If more facilities could allow women to bring 
their children with them, research suggests that retention would be 
universally increased.64 This also helps to reinforce a family-dynamic, 
which is significant because home life and support systems are so 
critical to substance abuse. A lack of familial-support, chaotic home 
lives and excess stress are all associated with the onset of SA,17 and it 
is crucial to address these factors when attempting to treat it. A focus 
on social aspects such as; relationship building, improving family-
relations and making ‘healthier’ choices in peers and partners would 
benefit treatment-seeking women greatly.70,71
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